Agios Opens Doors To Other Investors, Expands Into Genetic Disorders
This article was originally published in The Pink Sheet Daily
Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.
You may also be interested in...
Biotech’s decision on which candidate to advance to pivotal studies in pyruvate-kinase R deficiency is clarified as backup candidate AG-519 is placed on clinical hold and shelved. Agios hopes to bring the first disease-modifying PKD drug therapy to market.
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.